Clinical Trials · NCT02863419
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 711
- Start date
- Aug 2016
- Locations
- 108 sites, 13 countries
- Primary endpoint
- Change in HbA1c (Week 26)